Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Más filtros










Intervalo de año de publicación
1.
Future Microbiol ; 15: 241-257, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-32271107

RESUMEN

Aim: We sought to characterize the contribution of the O-OTase, PglL, to virulence in two Burkholderia spp. by comparing isogenic mutants in Burkholderia pseudomallei with the related species, Burkholderia thailandensis. Materials & methods: We utilized an array of in vitro assays in addition to Galleria mellonella and murine in vivo models to assess virulence of the mutant and wild-type strains in each Burkholderia species. Results: We found that pglL contributes to biofilm and twitching motility in both species. PglL uniquely affected morphology; cell invasion; intracellular motility; plaque formation and intergenus competition in B. pseudomallei. This mutant was attenuated in the murine model, and extended survival in a vaccine-challenge experiment. Conclusion: Our data support a broad role for pglL in bacterial fitness and virulence, particularly in B. pseudomallei.


Asunto(s)
Proteínas Bacterianas/metabolismo , Burkholderia pseudomallei/enzimología , Burkholderia pseudomallei/patogenicidad , Hexosiltransferasas/metabolismo , Melioidosis/microbiología , Proteínas de la Membrana/metabolismo , Animales , Proteínas Bacterianas/genética , Burkholderia pseudomallei/genética , Modelos Animales de Enfermedad , Femenino , Hexosiltransferasas/genética , Humanos , Proteínas de la Membrana/genética , Ratones , Ratones Endogámicos BALB C , Virulencia
2.
Sci Rep ; 10(1): 3311, 2020 02 24.
Artículo en Inglés | MEDLINE | ID: mdl-32094451

RESUMEN

In the absence of a correlate(s) of protection against human tuberculosis and a validated animal model of the disease, tools to facilitate vaccine development must be identified. We present an optimised ex vivo mycobacterial growth inhibition assay (MGIA) to assess the ability of host cells within the lung to inhibit mycobacterial growth, including Bacille Calmette-Guérin (BCG) and Mycobacterium tuberculosis (MTB) Erdman. Growth of BCG was reduced by 0.39, 0.96 and 0.73 log10 CFU following subcutaneous (s.c.) BCG, intranasal (i.n.) BCG, or BCG s.c. + mucosal boost, respectively, versus naïve mice. Comparatively, a 0.49 (s.c.), 0.60 (i.n.) and 0.81 (s.c. + mucosal boost) log10 reduction in MTB CFU was found. A BCG growth inhibitor, 2-thiophenecarboxylic acid hydrazide (TCH), was used to prevent quantification of residual BCG from i.n. immunisation and allow accurate MTB quantification. Using TCH, a further 0.58 log10 reduction in MTB CFU was revealed in the i.n. group. In combination with existing methods, the ex vivo lung MGIA may represent an important tool for analysis of vaccine efficacy and the immune mechanisms associated with vaccination in the organ primarily affected by MTB disease.


Asunto(s)
Bioensayo/métodos , Pulmón/microbiología , Pulmón/patología , Mycobacterium tuberculosis/crecimiento & desarrollo , Animales , Vacuna BCG/inmunología , Recuento de Células , Células Cultivadas , Inmunización , Ratones Endogámicos C57BL , Mycobacterium tuberculosis/inmunología
3.
Vaccine ; 38(6): 1416-1423, 2020 02 05.
Artículo en Inglés | MEDLINE | ID: mdl-31862194

RESUMEN

Tuberculosis still claims more lives than any other pathogen, and a vaccine better than BCG is urgently needed. One of the challenges for novel TB vaccines is to protect against all Mycobacterium tuberculosis lineages, including the most virulent ones, such as the Beijing lineage. Here we developed a live attenuated M. tuberculosis mutant derived from GC1237, a Beijing strain responsible for tuberculosis outbreaks in the Canary Islands. The mutant strain is inactivated both in the Rv1503c gene, responsible for surface glycolipid synthesis, and in the two-component global regulator PhoPR. This double mutant is as safe as BCG in immunodeficient SCID mice. In immune-competent mice and guinea pigs, the mutant is as protective as BCG against M. tuberculosis strains of common lineage 4 (Euro-American). By contrast, in mice the vaccine is protective against a M. tuberculosis strain of lineage 2 (East-Asian, Beijing), while BCG is not. These results highlight differences in protection efficacy of live attenuated M. tuberculosis-derived vaccine candidates depending on their genetic background, and provide insights for the development of novel live vaccines against TB, especially in East-Asian countries where M. tuberculosis strains of the Beijing family are highly dominant.


Asunto(s)
Vacunas contra la Tuberculosis/inmunología , Tuberculosis , Animales , Vacuna BCG , Cobayas , Ratones , Ratones SCID , Mycobacterium tuberculosis/genética , Mycobacterium tuberculosis/inmunología , Tuberculosis/prevención & control , Vacunas Atenuadas/inmunología
4.
J Microbiol Biotechnol ; 29(3): 489-499, 2019 Mar 28.
Artículo en Inglés | MEDLINE | ID: mdl-30691253

RESUMEN

Subunit vaccines are safer and more stable than live vaccines although they have the disadvantage of eliciting poor immune response. To develop a subunit vaccine, an effective delivery system targeting the key elements of the protective immune response is a prerequisite. In this study, oxidized carbon nanospheres (OCNs) were used as a subunit vaccine delivery system and tuberculosis (TB) was chosen as a model disease. TB is among the deadliest infectious diseases worldwide and an effective vaccine is urgently needed. The ability of OCNs to deliver recombinant Mycobacterium tuberculosis (Mtb) proteins, Ag85B and HspX, into bone marrow derived macrophages (BMDMs) and dendritic cells (BMDCs) was investigated. For immunization, OCNs were mixed with the two TB antigens as well as the adjuvant monophosphoryl lipid A (MPL). The protective efficacy was analyzed in vaccinated mice by aerosol Mtb challenge with a virulent strain of Mtb and the bacterial burdens were measured. The results showed that OCNs are highly effective in delivering Mtb proteins into the cytosol of BMDMs and BMDCs. Upon immunization, this vaccine formula induced robust Th1 immune response characterized by cytokine profiles from restimulated splenocytes and specific antibody titer. More importantly, enhanced cytotoxic CD8⁺ T cell activation was observed. However, it did not reduce the bacteria burden in the lung and spleen from the aerosol Mtb challenge. Taken together, OCNs are highly effective in delivering subunit protein vaccine and induce robust Th1 and CD8⁺ T cell response. This vaccine delivery system is suitable for application in settings where cell-mediated immune response is needed.


Asunto(s)
Carbono/química , Sistemas de Liberación de Medicamentos/métodos , Nanosferas/química , Linfocitos T Citotóxicos/inmunología , Vacunas contra la Tuberculosis , Tuberculosis/prevención & control , Vacunas de Subunidad/química , Vacunas de Subunidad/inmunología , Aciltransferasas/genética , Adyuvantes Inmunológicos , Administración a través de la Mucosa , Animales , Antígenos Bacterianos/genética , Antígenos Bacterianos/inmunología , Proteínas Bacterianas/genética , Proteínas Bacterianas/inmunología , Médula Ósea , Citocinas/metabolismo , Células Dendríticas/efectos de los fármacos , Modelos Animales de Enfermedad , Femenino , Inmunidad Celular , Inmunización , Pulmón/microbiología , Macrófagos/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Mycobacterium tuberculosis/patogenicidad , Bazo/microbiología , Células TH1/efectos de los fármacos , Vacunas Atenuadas/administración & dosificación , Vacunas Atenuadas/inmunología , Vacunas de Subunidad/administración & dosificación , Vacunas Sintéticas
5.
F1000Res ; 7: 296, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30026926

RESUMEN

Background: The only available tuberculosis (TB) vaccine, Bacillus Calmette-Guérin (BCG), has variable efficacy. New vaccines are therefore urgently needed. Why BCG fails is incompletely understood, and the tools used for early assessment of new vaccine candidates do not account for BCG variability. Taking correlates of risk of TB disease observed in human studies and back-translating them into mice to create models of BCG variability should allow novel vaccine candidates to be tested early in animal models that are more representative of the human populations most at risk. Furthermore, this could help to elucidate the immunological mechanisms leading to BCG failure. We have chosen the monocyte to lymphocyte (ML) ratio as a correlate of risk of TB disease and have back-translated this into a mouse model. Methods: Four commercially available, inbred mouse strains were chosen. We investigated their baseline ML ratio by flow cytometry; extent of BCG-mediated protection from Mtb infection by experimental challenge; vaccine-induced interferon gamma (IFNγ) response by ELISPOT assay; and tissue distribution of BCG by plating tissue homogenates. Results: The ML ratio varied significantly between A/J, DBA/2, C57Bl/6 and 129S2 mice. A/J mice showed the highest BCG-mediated protection and lowest ML ratio, while 129S2 mice showed the lowest protection and higher ML ratio. We also found that A/J mice had a lower antigen specific IFNγ response than 129S2 mice. BCG tissue distribution appeared higher in A/J mice, although this was not statistically significant. Conclusions: These results suggest that the ML ratio has an impact on BCG-mediated protection in mice, in alignment with observations from clinical studies. A/J and 129S2 mice may therefore be useful models of BCG vaccine variability for early TB vaccine testing. We speculate that failure of BCG to protect from TB disease is linked to poor tissue distribution in a ML high immune environment.

6.
PLoS One ; 13(5): e0196202, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29771915

RESUMEN

Burkholderia pseudomallei, a gram-negative intracellular bacillus, is the causative agent of a tropical infectious disease called melioidosis. Bacterial ATP-binding cassette (ABC) transporters import and export a variety of molecules across bacterial cell membranes. At present, their significance in B. pseudomallei pathogenesis is poorly understood. We report here characterization of the BPSL1039-1040 ABC transporter. B. pseudomallei cultured in M9 medium supplemented with nitrate, demonstrated that BPSL1039-1040 is involved in nitrate transport for B. pseudomallei growth under anaerobic, but not aerobic conditions, suggesting that BPSL1039-1040 is functional under reduced oxygen tension. In addition, a nitrate reduction assay supported the function of BPSL1039-1040 as nitrate importer. A bpsl1039-1040 deficient mutant showed reduced biofilm formation as compared with the wild-type strain (P = 0.027) when cultured in LB medium supplemented with nitrate under anaerobic growth conditions. This reduction was not noticeable under aerobic conditions. This suggests that a gradient in oxygen levels could regulate the function of BPSL1039-1040 in B. pseudomallei nitrate metabolism. Furthermore, the B. pseudomallei bpsl1039-1040 mutant had a pronounced effect on plaque formation (P < 0.001), and was defective in intracellular survival in both non-phagocytic (HeLa) and phagocytic (J774A.1 macrophage) cells, suggesting reduced virulence in the mutant strain. The bpsl1039-1040 mutant was found to be attenuated in a BALB/c mouse intranasal infection model. Complementation of the bpsl1039-1040 deficient mutant with the plasmid-borne bpsl1039 gene could restore the phenotypes observed. We propose that the ability to acquire nitrate for survival under anaerobic conditions may, at least in part, be important for intracellular survival and has a contributory role in the pathogenesis of B. pseudomallei.


Asunto(s)
Transportadoras de Casetes de Unión a ATP/metabolismo , Proteínas Bacterianas/metabolismo , Biopelículas/crecimiento & desarrollo , Burkholderia pseudomallei/fisiología , Espacio Intracelular/microbiología , Macrófagos/microbiología , Melioidosis/inmunología , Transportadoras de Casetes de Unión a ATP/genética , Anaerobiosis , Animales , Proteínas Bacterianas/genética , Burkholderia pseudomallei/genética , Burkholderia pseudomallei/metabolismo , Burkholderia pseudomallei/patogenicidad , Supervivencia Celular , Modelos Animales de Enfermedad , Femenino , Células HeLa , Humanos , Macrófagos/citología , Ratones , Ratones Endogámicos BALB C , Mutación , Nitritos/metabolismo , Fenotipo , Virulencia
7.
PLoS Pathog ; 12(7): e1005770, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-27467705

RESUMEN

Mycobacterium tuberculosis (Mtb), possesses at least three type VII secretion systems, ESX-1, -3 and -5 that are actively involved in pathogenesis and host-pathogen interaction. We recently showed that an attenuated Mtb vaccine candidate (Mtb Δppe25-pe19), which lacks the characteristic ESX-5-associated pe/ppe genes, but harbors all other components of the ESX-5 system, induces CD4+ T-cell immune responses against non-esx-5-associated PE/PPE protein homologs. These T cells strongly cross-recognize the missing esx-5-associated PE/PPE proteins. Here, we characterized the fine composition of the functional cross-reactive Th1 effector subsets specific to the shared PE/PPE epitopes in mice immunized with the Mtb Δppe25-pe19 vaccine candidate. We provide evidence that the Mtb Δppe25-pe19 strain, despite its significant attenuation, is comparable to the WT Mtb strain with regard to: (i) its antigenic repertoire related to the different ESX systems, (ii) the induced Th1 effector subset composition, (iii) the differentiation status of the Th1 cells induced, and (iv) its particular features at stimulating the innate immune response. Indeed, we found significant contribution of PE/PPE-specific Th1 effector cells in the protective immunity against pulmonary Mtb infection. These results offer detailed insights into the immune mechanisms underlying the remarkable protective efficacy of the live attenuated Mtb Δppe25-pe19 vaccine candidate, as well as the specific potential of PE/PPE proteins as protective immunogens.


Asunto(s)
Antígenos Bacterianos/inmunología , Proteínas Bacterianas/inmunología , Vacunas contra la Tuberculosis/inmunología , Tuberculosis Pulmonar/inmunología , Animales , Linfocitos T CD4-Positivos/inmunología , Reacciones Cruzadas , Modelos Animales de Enfermedad , Femenino , Citometría de Flujo , Ratones , Ratones Endogámicos C57BL , Mycobacterium tuberculosis/inmunología , Células TH1
8.
Vaccine ; 34(23): 2616-21, 2016 05 17.
Artículo en Inglés | MEDLINE | ID: mdl-27091689

RESUMEN

Burkholderia pseudomallei is the causative agent of melioidosis, which is associated with a range of clinical manifestations, including sepsis and fatal pneumonia and is endemic in Southeast Asia and Northern Australia. Treatment can be challenging and control of infection involves prolonged antibiotic therapy, yet there are no approved vaccines available to prevent infection. Our aim was to develop and assess the potential of a prophylactic vaccine candidate targeted against melioidosis. The identified candidate is the 22kDa outer membrane protein, OmpW. We previously demonstrated that this protein was immunoprotective in mouse models of Burkholderia cepacia complex (Bcc) infections. We cloned Bp_ompW in Escherichia coli, expressed and purified the protein. Endotoxin free protein administered with SAS adjuvant protected Balb/C mice (75% survival) relative to controls (25% survival) (p<0.05). A potent serological response was observed with IgG2a to IgG1 ratio of 6.0. Furthermore C57BL/6 mice were protected for up to 80 days against a lethal dose of B. pseudomallei and surpassed the efficacy of the live attenuated 2D2 positive control. BpompW is homologous across thirteen sequenced B. pseudomallei strains, indicating that it should be broadly protective against B. pseudomallei. In conclusion, we have demonstrated that BpOmpW is able to induce protective immunity against melioidosis and is likely to be an effective vaccine antigen, possibly in combination with other subunit antigens.


Asunto(s)
Antígenos Bacterianos/inmunología , Proteínas de la Membrana Bacteriana Externa/inmunología , Vacunas Bacterianas/inmunología , Melioidosis/prevención & control , Adyuvantes Inmunológicos/administración & dosificación , Animales , Anticuerpos Antibacterianos/sangre , Burkholderia pseudomallei , Femenino , Inmunoglobulina G/sangre , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Vacunas de Subunidad/inmunología
9.
Infect Immun ; 84(3): 701-10, 2015 Dec 28.
Artículo en Inglés | MEDLINE | ID: mdl-26712202

RESUMEN

Burkholderia pseudomallei, the causative agent of melioidosis, has complex and poorly understood extracellular and intracellular lifestyles. We used transposon-directed insertion site sequencing (TraDIS) to retrospectively analyze a transposon library that had previously been screened through a BALB/c mouse model to identify genes important for growth and survival in vivo. This allowed us to identify the insertion sites and phenotypes of negatively selected mutants that were previously overlooked due to technical constraints. All 23 unique genes identified in the original screen were confirmed by TraDIS, and an additional 105 mutants with various degrees of attenuation in vivo were identified. Five of the newly identified genes were chosen for further characterization, and clean, unmarked bpsl2248, tex, rpiR, bpsl1728, and bpss1528 deletion mutants were constructed from the wild-type strain K96243. Each of these mutants was tested in vitro and in vivo to confirm their attenuated phenotypes and investigate the nature of the attenuation. Our results confirm that we have identified new genes important to in vivo virulence with roles in different stages of B. pseudomallei pathogenesis, including extracellular and intracellular survival. Of particular interest, deletion of the transcription accessory protein Tex was shown to be highly attenuating, and the tex mutant was capable of providing protective immunity against challenge with wild-type B. pseudomallei, suggesting that the genes identified in our TraDIS screen have the potential to be investigated as live vaccine candidates.


Asunto(s)
Proteínas Bacterianas/metabolismo , Burkholderia pseudomallei/crecimiento & desarrollo , Burkholderia pseudomallei/metabolismo , Melioidosis/microbiología , Factores de Virulencia/metabolismo , Animales , Proteínas Bacterianas/genética , Burkholderia pseudomallei/genética , Femenino , Humanos , Ratones , Ratones Endogámicos BALB C , Viabilidad Microbiana , Factores de Virulencia/genética
10.
Arzneimittelforschung ; 57(6): 339-46, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17688079

RESUMEN

The acute toxicity of six quinoxaline 1,4-di-N-oxides has been evaluated in an attempt to determine: a) the feasibility of testing systemic toxicity of these compounds in a very preliminary phase without an adequate formulation for in vivo administration, b) the LD50 range and the toxic target organ of these compounds in order to have an approximation of the structure-activity relationship. Quinoxaline 1,4-di-N-oxides have shown a great variety of biological activities with potential therapeutic application in cancer, malaria, etc. Problems of toxicity hinder the progression of these compounds to clinical phases. The compounds dissolved in DMSO at their solubility limit were administered i.v. to female Wistar rats (8 weeks, 160 g), using an infusion pump (300 microL; 20 microl/min). Animals were observed for a period of 14 days. This dose of the vehicle (1.7 ml/kg) was well tolerated by the animals. The LD50 could not be determined, but a marked hypoactivity was induced by the treatment. The same compounds were also injected intraperitoneally, suspended in 0.01% Tween 80/0.09 % saline, and the animals that did not die were observed for a period of 14 days. The LD50 could be estimated to be in a range between 30 and 120 mg/kg, except for one of the compounds. A decrease in the evolution of body weight and hypoactivity were the principal symptoms induced by the treatment. In both assays, histopathologic study of heart, liver, kidney, lung, spleen and ovaries indicated that the target organs may be heart and spleen. In conclusion, the i.v. route is not adequate for estimating the LD50 of these compounds due to solubility problems; by i.p. route, the LD50 interval is between 30 and 120 mg/kg. The data did not permit the deduction of any specific structure-activity relationship.


Asunto(s)
Concentración de Iones de Hidrógeno , Quinoxalinas/toxicidad , Animales , Peso Corporal/efectos de los fármacos , Dimetilsulfóxido/toxicidad , Relación Dosis-Respuesta a Droga , Femenino , Inyecciones Intraperitoneales , Inyecciones Intravenosas , Dosificación Letal Mediana , Quinoxalinas/química , Ratas , Ratas Wistar , Solubilidad , Relación Estructura-Actividad
11.
Acta psiquiátr. psicol. Am. Lat ; 31(1): 25-36, mar. 1985. ilus, tab
Artículo en Español | LILACS | ID: lil-1589

RESUMEN

El dosaje de catecolaminas urinarias en 472 casos de depresión muestra la estrecha relación entre los resultados de labor torio y la sintomatología. A partir de esos datos se evalúa la eficacia terapéutica de las aminas biógenas precursoras de los neurotransmisores. Las conclusiones confirman ambas hipótesis de trabajo en un estudi comparativo con un grupo control tratado mediante antidepresivos


Asunto(s)
Niño , Adolescente , Adulto , Persona de Mediana Edad , Humanos , Masculino , Femenino , Catecolaminas/orina , Trastorno Depresivo/orina , Neurotransmisores/metabolismo , Trastornos de Adaptación/tratamiento farmacológico , Antidepresivos/uso terapéutico , Trastorno Depresivo/tratamiento farmacológico , Imipramina/uso terapéutico , Trastornos del Humor/tratamiento farmacológico , Trastornos Neuróticos/tratamiento farmacológico
12.
Acta psiquiátr. psicol. Am. Lat ; 31(1): 25-36, mar. 1985. ilus, tab
Artículo en Español | BINACIS | ID: bin-36988

RESUMEN

El dosaje de catecolaminas urinarias en 472 casos de depresión muestra la estrecha relación entre los resultados de labor torio y la sintomatología. A partir de esos datos se evalúa la eficacia terapéutica de las aminas biógenas precursoras de los neurotransmisores. Las conclusiones confirman ambas hipótesis de trabajo en un estudi comparativo con un grupo control tratado mediante antidepresivos (AU)


Asunto(s)
Niño , Adolescente , Adulto , Persona de Mediana Edad , Anciano , Humanos , Masculino , Femenino , Estudio Comparativo , Catecolaminas/orina , Trastorno Depresivo/orina , Neurotransmisores/metabolismo , Antidepresivos/uso terapéutico , Trastornos de Adaptación/tratamiento farmacológico , Trastorno Depresivo/tratamiento farmacológico , Trastornos del Humor/tratamiento farmacológico , Trastornos Neuróticos/tratamiento farmacológico , Imipramina/uso terapéutico
14.
Buenos Aires; La Semana Médica; 1940. 182 p. ilus. (61245).
Monografía en Español | BINACIS | ID: bin-61245
15.
16.
Buenos Aires; Kraft; 1953. 272 p.
Monografía en Español | LILACS-Express | BINACIS | ID: biblio-1210629
17.
Buenos Aires; Kraft; 1953. 272 p. (103963).
Monografía en Español | BINACIS | ID: bin-103963
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...